Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss
Sjaak Pouwels, Nasser Sakran, Yitka N. H. Graham, Angela Leal, Tadeja Pintar, Wah Yang, Radwan Kassir, Rishi Singhal, Kamal Kumar Mahawar, Dharmanand Ramnarain · 2022
Read Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss by Sjaak Pouwels, Nasser Sakran, Yitka N. H. Graham, Angela Leal, Tadeja Pintar, Wah Yang, Radwan Kassir, Rishi Singhal, Kamal Kumar Mahawar, Dharmanand Ramnarain (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/openalex-w4220832833.txt.
Description
Sjaak Pouwels, Nasser Sakran, Yitka Graham, and colleagues review non-alcoholic fatty liver disease, in BMC Endocrine Disorders in 2022. The disease, shortened to NAFLD, is now the most common chronic liver condition in the Western world. It tracks closely with obesity, diabetes, high blood pressure, and abnormal blood fats. Damage ranges from simple fat build-up to inflamed, scarred liver failure.
Scarring, called fibrosis, is the strongest sign of future illness and liver-related death. A liver biopsy remains the standard way to confirm the disease and its stage. Once diagnosed, weight loss, diet change, and treating the wider metabolic syndrome stay the mainstays of therapy. The review covers causes, day-to-day management, and what weight loss can achieve.
Catalog record
| CREATOR | Sjaak Pouwels, Nasser Sakran, Yitka N. H. Graham, Angela Leal, Tadeja Pintar, Wah Yang, Radwan Kassir, Rishi Singhal, Kamal Kumar Mahawar, Dharmanand Ramnarain |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | OpenAlex / BMC Endocrine Disorders |